FDA Fast Track Designation: What It Is & How to Get It
Fast Track is the earliest and most accessible of the FDA’s four expedited programs. Here is exactly what qualifies, what the designation buys you, how to request it, how it relates to Breakthrough Therapy, Accelerated Approval and Priority Review — and what it does, and does not, signal in a licensing diligence.
What Fast Track Is
Fast Track is one of the FDA’s four expedited programs for serious conditions, alongside Breakthrough Therapy, Accelerated Approval, and Priority Review. Its statutory home is Section 506 of the Federal Food, Drug, and Cosmetic Act. The purpose is narrow and practical: to facilitate the development and expedite the review of a drug or biologic that treats a serious or life-threatening condition and that fills an unmet medical need.
The single most important thing to understand about Fast Track is that it is a process designation, not an efficacy verdict. It does not lower the evidentiary bar for approval, it does not promise a faster review clock by itself, and it certainly does not say the FDA thinks the drug works. What it does is open earlier, more frequent, and more structured engagement with the Agency, and unlock features — chiefly rolling review — that can compress the back end of development. For a sponsor or a licensor, that distinction is everything: Fast Track is a tool for running the program better, not a shortcut around the data.
It is also the most accessible of the four programs. Because it can be granted on early, even pre-clinical evidence, a sponsor can often hold a Fast Track designation long before there is any human efficacy signal — which is precisely why a Fast Track in a press release should be read carefully rather than celebrated reflexively.
The Two Criteria
A drug qualifies for Fast Track if it meets two requirements. Both must hold.
- A serious or life-threatening condition. Whether a condition counts as serious turns on its effect on survival, day-to-day functioning, or the likelihood that, left untreated, it progresses from a less severe to a more serious state. Cancer, heart failure, and many rare diseases clearly qualify; so can conditions that are serious in their persistent or progressive form.
- The potential to address an unmet medical need. The therapy must provide a treatment where none exists, or show potential to be better than available therapy — for example, superior effectiveness, an improved effect on serious outcomes, avoidance of serious side effects, improved diagnosis where earlier diagnosis improves outcomes, or a benefit for patients who cannot tolerate existing options.
The crucial nuance — and the reason Fast Track sits at the bottom of the evidence ladder — is what counts as proof of that potential. The FDA can grant Fast Track based on nonclinical or clinical data, and at an early stage that can mean evidence of activity in a nonclinical model, pharmacologic data, or a sound mechanistic rationale. You do not need human efficacy data to qualify. That is the defining contrast with Breakthrough Therapy, which we return to below.
Read “unmet need” as a moving target
What You Actually Get
Fast Track confers a defined set of features. None of them is approval, and none guarantees a faster verdict on its own — but together they can materially de-risk and accelerate a program.
- More frequent interaction with the FDA. Meetings and written communication beyond the standard pre-IND, end-of-Phase-1, end-of-Phase-2, and pre-NDA/BLA cadence — covering trial design, biomarkers, and the contents of the marketing application. Getting the development plan right early is, in expected-value terms, often the most valuable benefit of all.
- Rolling review. Eligibility to submit completed portions of the NDA or BLA for review as they are finished, rather than waiting to file the entire application at once. Rolling submission is available only to Fast Track and Breakthrough Therapy products, and it can pull the review start date forward.
- A foundation for later designations. Fast Track makes a product eligible to be considered for Accelerated Approval and Priority Review — provided each of those separate criteria is independently met.
Eligibility is not entitlement
How and When to Request It
Fast Track is sponsor-initiated — the FDA does not award it on its own motion. The mechanics are straightforward, and the timing flexibility is one of the program’s genuine advantages.
- When. The request can be submitted with the original IND or at any time thereafter. The FDA’s practical guidance is to request it no later than the pre-NDA or pre-BLA meeting, since the benefits accrue during development and a late request leaves little runway to use them.
- What to include. A request must present the nonclinical or clinical data that support the serious-condition and unmet-need rationale. Early in development that can rest on a mechanistic argument and nonclinical activity; later it should lean on whatever clinical data exist.
- The clock. The FDA aims to respond within 60 calendar days of receiving the request. A grant is specific to the drug-plus-indication combination, not the molecule in the abstract.
Because the bar is low and the request is cheap relative to a clinical program, Fast Track is frequently the first expedited designation a serious-condition asset pursues — a sensible early move that sets up the FDA relationship and keeps the door open to the later, higher-bar programs. For where this sits in the broader development arc, see our guide to the stages of drug development.
Fast Track vs the Other Three Programs
The four expedited programs are routinely confused, in part because they overlap and a single asset can hold several at once. The cleanest way to keep them straight is to ask what each one is fundamentally about.
- Fast Track is about engagement and process, granted early on the potential to address an unmet need.
- Breakthrough Therapy is about preliminary clinical proof — it requires evidence that the drug may offer substantial improvement over available therapy on a clinically significant endpoint, and it layers more intensive FDA guidance on top of every Fast Track feature. See our dedicated Breakthrough Therapy guide.
- Accelerated Approval is about the basis of approval — it allows approval on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit, with required confirmatory post-marketing trials.
- Priority Review is about the review clock — it directs the FDA to aim to act within roughly six months instead of the standard ten.
These are not mutually exclusive. A serious-condition oncology asset might be granted Fast Track early, earn Breakthrough Therapy once a striking Phase II response rate emerges, file under Accelerated Approval on that response-rate surrogate, and receive Priority Review of the application. Knowing which lever applies at which stage — and what evidence each demands — is the core competence here.
The Four Programs Compared
The table below summarizes the four expedited programs on the dimensions that matter most when planning a program or reading a diligence file.
Fast Track vs Breakthrough Therapy — the two development-stage designations
| Dimension | Fast Track | Breakthrough Therapy |
|---|---|---|
Core question Fast Track facilitates development and review; Breakthrough adds intensive guidance once early human data look strong. | Engagement and process | Preliminary clinical proof |
Evidence required This is the defining difference — Fast Track can be granted on a mechanistic rationale; Breakthrough cannot. | Nonclinical or clinical data; mechanism can suffice | Preliminary clinical evidence of substantial improvement |
Endpoint standard Breakthrough requires a comparison against available therapy on a meaningful endpoint. | Potential to address an unmet medical need | Substantial improvement on a clinically significant endpoint |
Rolling review Both unlock rolling submission of the NDA/BLA; the other two programs do not. | Eligible | Eligible |
FDA decision target Both are sponsor-requested designations with a 60-day FDA response goal. | Within 60 days of request | Within 60 days of request |
The other two programs operate later and on different logic. Accelerated Approval changes the basis of approval — permitting it on a surrogate endpoint reasonably likely to predict clinical benefit, conditional on confirmatory Phase IV trials. Priority Review changes the review clock — targeting action in about six months versus the standard ten, granted at the time of the marketing application rather than during development. Neither is requested the way Fast Track and Breakthrough are; both are assessed against their own criteria when the relevant filing is made.
Examples and Numbers
Fast Track is, by design, common — far more common than Breakthrough Therapy. The CDER granted Fast Track to 187 drugs in 2020, of which 36 had been approved as of the relevant reporting. That volume tells you something important: a Fast Track designation is a meaningful signal that an asset addresses a serious condition, but it is not a rare badge of distinction. The programs sit on a deliberate ladder — many assets get Fast Track, fewer earn Breakthrough Therapy, and fewer still secure Accelerated Approval.
The everyday pattern is sequential. A sponsor obtains Fast Track at or near IND to set up the FDA relationship; if the first solid clinical readout shows a striking effect, it then applies for Breakthrough Therapy; and at filing it pursues Priority Review and, where the data support a surrogate, Accelerated Approval. Each step is gated by stronger evidence than the last — which is exactly why the later designations carry more weight in a valuation.
The BD and Licensing Read
For a business-development or licensing audience, the question is never simply “does the asset have Fast Track?” It is what the designation actually tells you, and how to weigh it against everything else in the data room.
- What it signals. That the FDA accepts the serious-condition framing and the unmet-need rationale, and that the sponsor is engaged with the Agency in a structured way. That is real and useful — it de-risks the regulatory posture of the program.
- What it does not signal. Efficacy. Because Fast Track can rest on a mechanistic rationale, its presence says little about whether the drug works. Do not let a Fast Track line in a teaser inflate the perceived clinical de-risking of an early asset.
- Sequencing as a tell. The more informative read is the ladder. An asset that holds Fast Track but has not, after meaningful clinical data, progressed to Breakthrough Therapy may be telling you the human data are not yet differentiating — a question worth pressing in diligence rather than assuming.
- Transferability. Designations attach to the program and move with the asset, but a licensee should confirm the FDA correspondence, the designation letter, and the indication scope in diligence rather than relying on a summary.
In short, treat Fast Track as a regulatory hygiene factor and a sequencing milestone, not as evidence of efficacy. The valuation work lives in the clinical data and the unmet-need thesis behind the designation — which is the same discipline we bring to the underlying regulatory pathway questions in our 505(b)(2) pathway guide.
The China / NMPA Analog
For cross-border programs, it helps to know the Chinese counterpart. China’s National Medical Products Administration (NMPA) runs four accelerated registration procedures: Breakthrough Therapy, Conditional Approval, Priority Review, and Special Review and Approval.
The closest analog to the review-acceleration role is the NMPA Priority Review and Approval procedure, which targets roughly 130 working days — about six months — from NDA submission for qualifying assets such as innovative drugs and those for rare diseases, pediatric populations, and urgent clinical needs. The NMPA Breakthrough Therapy procedure is the closer analog to the development-stage support of Fast Track and Breakthrough combined: it enables rolling NDA submission and frequent technical consultations with reviewers during clinical development, for drugs treating serious conditions with significant clinical advantage. Conditional Approval is China’s surrogate-endpoint pathway, parallel in spirit to Accelerated Approval.
The practical point for a cross-border dealmaker: these designations are jurisdiction-specific. A US Fast Track does not carry to China, and an NMPA Priority Review does not carry to the FDA. A global program pursues the relevant expedited status in each agency on its own criteria and timeline. We track Chinese approvals and the NMPA pathway dynamics in our NMPA approvals tracker.
The Bottom Line
Fast Track is the entry rung of the FDA’s expedited ladder: easy to qualify for, valuable for the FDA engagement and rolling review it unlocks, and an enabler — not a guarantee — of the higher programs that follow. Understood properly, it is a tool for running a serious-condition program well, not a marketing claim about efficacy.
For anyone underwriting an asset, the discipline is to read Fast Track for exactly what it is worth: confirmation that the FDA recognizes the serious-condition and unmet-need framing, paired with the harder question of whether the clinical data behind it justify the designation today. If you are evaluating a designated asset for an in-licensing or partnership decision, or planning the regulatory sequencing for a cross-border program, talk to our team.